REG - Immupharma PLC - Realisation-c£1.5m on sale of shares in Incanthera

ImmuPharmaAnnouncement

03/06/2024 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC8529Qa&default-theme=true

RNS Number : 8529Q  Immupharma PLC  03 June 2024

 

RNS | 3 June 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Realisation of c£1.5 million on sale of shares in Incanthera plc

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, announces that it has realised gross proceeds of c£1.5 million on
the sale of its entire holding of c9.9 million shares in Incanthera plc.

 

Following this transaction, ImmuPharma retains c7.3 million warrants in
Incanthera plc which have an exercise price of 9.5p and exercise expiry date
of 6 September 2024.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Dr Tim Franklin, COO

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical analysis
suggests P140 may have therapeutic benefit in many other autoimmune diseases
that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma.co.uk) .co.uk (http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISFIFIARVIVIIS